latest news releases from the newsroom
FTS Wireless, Inc.
FTS Wireless Chairman and CEO Interviewed on Business Talk Radio Show
YARDLEY, Pa., Dec. 01,2003 (PRIMEZONE) -- FTS Wireless, Inc., (OTCBB:FLIP) a next generation wireless acquisition and development company and wholly owned subsidiary of FTS Apparel, Inc., would like to inform its shareholders and other interested parties that its Chairman and Chief Executive Officer Mr. Scott Gallagher was interviewed on a financial program that ran last night on some 350 radio channels across the U.S. The program also featured an interview with noted fund manager and Chairman of Gabelli Asset Management, Inc. (NYSE:GBL) Mr. Mario Gabelli.
CDMA Development Group
CDG Congratulates KDDI on Deployment of CDMA2000 1xEV-DO
COSTA MESA, Calif., Dec. 1, 2003 (PRIMEZONE) -- The CDMA Development Group (CDG) (www.cdg.org) congratulates KDDI on the launch of CDMA2000(r) 1xEV-DO services in major metropolitan areas in Japan. Branded CDMA 1X WIN, the new service complements KDDI's already successful EZWeb product and will enable the operator to offer most advanced broadband applications. KDDI is the ninth carrier worldwide to commercially deploy CDMA2000 1xEV-DO.
Medivir and Peptimmune announce EU patent on uses of cathepsin S
HUDDINGE, Sweden, Dec. 1, 2003 (PRIMEZONE) -- Peptimmune, Inc. and Medivir today announced the issuance of a European patent claiming uses of Cathepsin S inhibitors in therapeutic formulations for suppressing immune responses. European patent 0912601 issued on November 26, 2003, and is entitled "SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S."
Akzo Nobel Opens New Biotech Vaccines Facility
ARNHEM, The Netherlands, Dec. 1, 2003 (PRIMEZONE) -- Akzo Nobel officially opened its new biotech vaccines production facility in Boxmeer this afternoon. The opening ceremony was performed by Secretary-General for Economic Affairs, Mr. J.W. Oosterwijk, acting on behalf of the Dutch Minister of Economic Affairs, Mr. L.J. Brinkhorst. The state-of-the-art Nobilon facility will produce vaccines for Akzo Nobel's animal healthcare business Intervet and at the same time function as a platform for exploring opportunities in the human vaccines field.